We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





Saladax Biomedical Launches Game-Changing Assays at AACC 2018

By LabMedica International staff writers
Posted on 31 Jul 2018
Print article
Image: Saladax Biomedical has launched a new line of tests for psychiatry in Europe (Photo courtesy of Saladax Biomedical).
Image: Saladax Biomedical has launched a new line of tests for psychiatry in Europe (Photo courtesy of Saladax Biomedical).
Saladax Biomedical Inc. (Bethlehem, PA, USA), a diagnostics company providing kits to test drug blood levels for adherence and personalized dose management, announced the launch of its new line of tests for psychiatry in Europe (CE mark) at AACC 2018. Saladax develops novel blood tests that increase the impact of personalized medicine by bringing chemotherapeutic drug monitoring to oncologists and adherence testing to psychiatrists.

Saladax’s MyCare Psychiatry line provides greater clarity on the causes of treatment failure and may help distinguish medication non-response from lack of adherence. The MyCare Psychiatry panel of tests addresses a critical, unmet need for quickly identifying levels of antipsychotic drugs in a patient’s body. A one-hour turnaround time is possible in a STAT mode within a laboratory. Rapid testing has the potential to reduce treatment failures and to positively impact patient management. The MyCare Psychiatry line will launch with tests for clozapine, quetiapine, aripiprazole, risperidone, olanzapine and paliperidone, five of which are currently available for sale in Europe.

“We engineered the MyCare Psychiatry line based on psychiatrists’ needs and extensive research of the market,” said Dr. Salvatore J. Salamone, Founder/CEO. “The result is a game-changer that delivers clinicians access to rapid quantitative blood levels of the psychotherapeutic drugs their patients are on. The MyCare line delivers a fast and accurate result, giving physicians timely information of high medical value, needed to better treat their patients.”

Related Links:
Saladax Biomedical

New
Gold Supplier
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
New
Real-Time Fluorescent Quantitative PCR System
AccuRa-32
New
Data Management Software
DataSite
New
Rapid Procalcitonin (PCT) Test
AQT90 FLEX PCT Assay

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.